Abstract
Antipsychotic agents have limited efficacy for Behavioral and Psychological Symptoms of Dementia (BPSD) and there are concerns about their safety. Despite this, they are frequently used for the management of BPSD. This study aimed to assess the use of antipsychotics among people on anti-dementia medicines in Australian residential aged care facilities. Data were obtained from an individual patient unit dose packaging database covering 40 residential aged care facilities in New South Wales, Australia. Residents supplied an anti-dementia medicine between July 2008 and June 2013 were included. Prevalence of concurrent antipsychotic use was established. Incident antipsychotic users between January 2009 and December 2011 were identified. We examined initial antipsychotic dose, maximum titrated doses, type and duration of antipsychotic use, and compared use with Australian guidelines. There were 291 residents treated with anti-dementia medicines, 129 (44%) of whom received antipsychotics concomitantly with an anti-dementia medicine. Among the 59 incident antipsychotic users, risperidone (73%) was the most commonly used antipsychotic agent. Amongst the risperidone initiators, 43% of patients had initial doses greater than 0.5 mg/day a...Continue Reading
References
Aug 17, 1999·Archives of Internal Medicine·J Cohen-MansfieldR Woosley
Sep 24, 2002·International Psychogeriatrics·Robert van ReekumLaurie Ostrander
Feb 3, 2005·JAMA : the Journal of the American Medical Association·Kaycee M SinkKristine Yaffe
Nov 30, 2005·International Journal of Geriatric Psychiatry·John SnowdonWesley Baker
Jul 6, 2006·International Journal of Geriatric Psychiatry·John SnowdonSue Day
Apr 4, 2008·PLoS Medicine·Clive BallardUNKNOWN Investigators DART AD
Jan 14, 2009·Lancet Neurology·Clive BallardUNKNOWN DART-AD investigators
Oct 14, 2009·International Journal of Geriatric Psychiatry·I TestadD Aarsland
Jan 13, 2010·Archives of Internal Medicine·Yong ChenJerry H Gurwitz
Mar 24, 2010·The Australian and New Zealand Journal of Psychiatry·Samantha A HollingworthWayne D Hall
Jun 18, 2010·Australasian Journal on Ageing·Juanita WestburyGregory Peterson
Jun 29, 2010·Pharmacoepidemiology and Drug Safety·Nicole PrattAmy Salter
Oct 23, 2010·Drugs & Aging·Nicole L PrattPhilip Ryan
Dec 16, 2010·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Roland B WetzelsRaymond T C M Koopmans
Mar 25, 2011·International Psychogeriatrics·John SnowdonDivya Vaswani
Jun 15, 2011·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Nicole PrattPhilip Ryan
Jun 21, 2011·International Psychogeriatrics·R B WetzelsR T C M Koopmans
May 16, 2012·Frontiers in Neurology·J CerejeiraE B Mukaetova-Ladinska
Feb 9, 2013·BMC Pharmacology & Toxicology·Maria GustafssonHugo Lövheim
Oct 26, 2013·Dementia and Geriatric Cognitive Disorders·Yi-Ju PanSube Banerjee
May 6, 2014·The Medical Journal of Australia·Lynn M Weekes
Jun 21, 2014·The Australian and New Zealand Journal of Psychiatry·Ji Hyun BaekGustavo Kinrys
Aug 8, 2014·Australian Health Review : a Publication of the Australian Hospital Association·Loc P ThaiJohn R Moss
Citations
Oct 4, 2016·Journal of Neurosciences in Rural Practice·Vaios PeritogiannisVenetsanos Mavreas
Aug 30, 2018·Dementia·Kerrie WestawayElizabeth Roughead
Feb 27, 2018·BMC Geriatrics·Stephanie L HarrisonMaria Crotty
Mar 26, 2019·International Journal of Geriatric Psychiatry·Kimberly E LindJohanna I Westbrook
Jul 26, 2019·Alzheimer Disease and Associated Disorders·Kimberly E LindJohanna I Westbrook
Apr 13, 2018·American Journal of Alzheimer's Disease and Other Dementias·Tuan Anh NguyenElizabeth E Roughead
Jul 25, 2019·Pharmacy : Journal of Pharmacy, Education and Practice·Lisa M Kalisch EllettElizabeth E Roughead
Jun 13, 2021·Trials·Sam KosariRachel Davey